• Philadelphia International Medicine

Gene Editing Technology Harnessed to Identify New, Druggable Targets in Kidney Cancer

PHILADELPHIA (November 5, 2020) – Researchers at Fox Chase Cancer Center have harnessed the power of the Nobel Prize-winning CRISPR/Cas9 technology to identify cellular factors involved in resistance to sunitinib by clear cell renal cell carcinoma.